|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
SG11201907299XA
(en)
|
2017-02-08 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
IL268755B2
(en)
|
2017-02-20 |
2025-12-01 |
Dragonfly Therapeutics Inc |
Proteins that bind her2, nkg2d, and cd16
|
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
AU2018322178A1
(en)
*
|
2017-08-23 |
2020-02-20 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3740505A1
(en)
*
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
EA202091887A1
(ru)
|
2018-02-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
AU2019228128A1
(en)
*
|
2018-03-02 |
2020-09-03 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
WO2019222449A1
(en)
*
|
2018-05-16 |
2019-11-21 |
Dragonfly Therapeutics, Inc. |
Protein binding nkg2d, cd16 and a fibroblast activation protein
|
|
CA3099308A1
(en)
*
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
US12378318B2
(en)
|
2018-08-08 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and a tumor-associated antigen
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
WO2020033630A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
EP3966247B1
(en)
*
|
2019-05-06 |
2026-01-07 |
Brown University |
Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
CN116574183A
(zh)
*
|
2019-08-22 |
2023-08-11 |
盛禾(中国)生物制药有限公司 |
多功能抗体、其制备及其用途
|
|
CN112409484B
(zh)
*
|
2019-08-22 |
2023-03-21 |
盛禾(中国)生物制药有限公司 |
多功能抗体、其制备及其用途
|
|
TWI888487B
(zh)
*
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
MX2023000005A
(es)
*
|
2020-06-26 |
2023-03-06 |
Sorrento Therapeutics Inc |
Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
|
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20250215081A1
(en)
|
2020-11-06 |
2025-07-03 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
CN114736291B
(zh)
*
|
2021-01-07 |
2023-08-11 |
中国科学院微生物研究所 |
特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
|
|
WO2022170619A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
JP2024508894A
(ja)
|
2021-03-03 |
2024-02-28 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
|
|
WO2022200478A1
(en)
*
|
2021-03-24 |
2022-09-29 |
Pieris Pharmaceuticals Gmbh |
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
|
|
US20240218065A1
(en)
*
|
2021-06-15 |
2024-07-04 |
Shenghe (China) Biopharmaceutical Co. |
Multispecific antigen-binding protein and use thereof
|
|
CA3216098A1
(en)
*
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
US20240327543A1
(en)
*
|
2021-08-02 |
2024-10-03 |
Shenghe (China) Biopharmaceutical Co., Ltd. |
Multispecific antigen-binding protein and use thereof
|
|
WO2023192973A1
(en)
*
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|